Neothetics Provides Business Update and Reports First Quarter 2017 Financial Results
May 11, 2017 08:00 ET
|
Neothetics, Inc.
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today provided a...
Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
March 20, 2017 08:00 ET
|
Neothetics, Inc.
SAN DIEGO, March 20, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced...
Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
December 23, 2016 08:00 ET
|
Neothetics, Inc.
SAN DIEGO, Dec. 23, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced the initiation of the Phase 2 proof of concept trial, LIPO-202-CL-31, for LIPO-202 for the reduction of...
Neothetics Provides Business Update and Reports Third Quarter 2016 Financial Results
November 10, 2016 08:00 ET
|
Neothetics, Inc.
SAN DIEGO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided a business update on its strategic initiatives and reported financial results for the third quarter 2016. ...
Neothetics Provides Update and Plan Forward for LIPO-202 Program
March 28, 2016 08:00 ET
|
Neothetics, Inc.
SAN DIEGO, March 28, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided an update and plan forward for its LIPO-202 program. Neothetics plans to initiate a Phase 2 trial with...
CORRECTION: The Roxbury Institute Hosts Grand Opening Party in Beverly Hills, California
March 22, 2016 13:43 ET
|
Dr. David Amron
Los Angeles, March 22, 2016 (GLOBE NEWSWIRE) -- An earlier version of this release stated that Dr. Jason Emer hosted a grand opening party Thursday at The Roxbury Institute at 450 N. Roxbury Drive,...
Neothetics Announces Leadership Change and Preliminary Update on LIPO-202
February 18, 2016 16:00 ET
|
Neothetics, Inc.
SAN DIEGO, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced...
Neothetics Initiates Pivotal Phase 3 Clinical Trials for LIPO-202, the First Non-Invasive Injectable Drug Candidate for Reduction of Subcutaneous Abdominal Fat
April 13, 2015 08:00 ET
|
Neothetics, Inc.
SAN DIEGO, April 13, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the...
Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results
March 26, 2015 08:00 ET
|
Neothetics, Inc.
SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported...
Neothetics to Present at the 27th Annual Roth Conference
March 04, 2015 08:00 ET
|
Neothetics, Inc.
SAN DIEGO, March 4, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that...